Evestia Clinical

Evestia Clinical is a global specialist Contract Research Organization (CRO) dedicated to accelerating the development of life-changing therapies for biotech innovators. Formerly known as EMAS Pharma and acquired by Kester Capital in December 2024, we entered a new chapter in 2025 through our strategic merger with Atlantic Research Group (ARG). Together, we have united two highly complementary organizations to create a leading mid-tier CRO with expanded global reach, enhanced therapeutic expertise, and a full-service clinical trial offering. With headquarters in Letchworth, UK, and Charlottesville, Virginia, USA, our combined team of over 150 professionals delivers tailored solutions across the full drug development lifecycle—from Phase 1 through Phase 3 and beyond. This merger strengthens our capabilities in oncology, rare diseases, immunology, and inflammation, while adding deep expertise in neurology and late-stage clinical trial services. Our clients benefit from: • Global Infrastructure: Seamless access to international trial networks and regulatory expertise. • Expanded Therapeutic Reach: Specialized services in high-research areas including ALS/MND, oncology, and neurology. • Integrated Technology Platforms: Enhanced data management, biostatistics, and trial oversight tools. • Experienced Leadership: A proven executive team with a track record of building market-leading CROs, now joined by ARG’s senior leadership. At Evestia Clinical, we empower biotech innovators by providing expert-driven, agile, and personalized clinical research solutions—accelerating the development of life-changing therapies with confidence and care.